Janone (ALTS) Competitors $3.55 -0.20 (-5.33%) (As of 03:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesSEC FilingsShort InterestTrends ALTS vs. BMEA, SOPH, XBIT, INBX, LFVN, CRDF, CMPX, MGNX, PRQR, and SLNShould you be buying Janone stock or one of its competitors? The main competitors of Janone include Biomea Fusion (BMEA), SOPHiA GENETICS (SOPH), XBiotech (XBIT), Inhibrx (INBX), LifeVantage (LFVN), Cardiff Oncology (CRDF), Compass Therapeutics (CMPX), MacroGenics (MGNX), ProQR Therapeutics (PRQR), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical products" industry. Janone vs. Biomea Fusion SOPHiA GENETICS XBiotech Inhibrx LifeVantage Cardiff Oncology Compass Therapeutics MacroGenics ProQR Therapeutics Silence Therapeutics Biomea Fusion (NASDAQ:BMEA) and Janone (NASDAQ:ALTS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, community ranking, analyst recommendations, profitability and risk. Which has higher earnings & valuation, BMEA or ALTS? Janone has higher revenue and earnings than Biomea Fusion. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-1.03Janone$7.11M7.32-$7.81MN/AN/A Do analysts prefer BMEA or ALTS? Biomea Fusion presently has a consensus target price of $39.36, indicating a potential upside of 848.52%. Given Biomea Fusion's stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Janone.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Janone 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is BMEA or ALTS more profitable? Biomea Fusion's return on equity of -118.90% beat Janone's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% Janone N/A -2,940.01%-39.81% Do institutionals & insiders believe in BMEA or ALTS? 96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 6.3% of Janone shares are owned by institutional investors. 27.6% of Biomea Fusion shares are owned by insiders. Comparatively, 4.9% of Janone shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media favor BMEA or ALTS? In the previous week, Biomea Fusion had 14 more articles in the media than Janone. MarketBeat recorded 14 mentions for Biomea Fusion and 0 mentions for Janone. Janone's average media sentiment score of 1.00 beat Biomea Fusion's score of 0.34 indicating that Janone is being referred to more favorably in the news media. Company Overall Sentiment Biomea Fusion Neutral Janone Positive Does the MarketBeat Community believe in BMEA or ALTS? Biomea Fusion received 56 more outperform votes than Janone when rated by MarketBeat users. CompanyUnderperformOutperformBiomea FusionOutperform Votes5668.29% Underperform Votes2631.71% JanoneN/AN/A Which has more volatility & risk, BMEA or ALTS? Biomea Fusion has a beta of -0.53, suggesting that its stock price is 153% less volatile than the S&P 500. Comparatively, Janone has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. SummaryBiomea Fusion beats Janone on 9 of the 14 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Janone News Delivered to You Automatically Sign up to receive the latest news and ratings for ALTS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALTS vs. The Competition Export to ExcelMetricJanonePharmaceutical IndustryFinance SectorNASDAQ ExchangeMarket Cap$52.06M$6.84B$10.49B$9.28BDividend YieldN/A3.06%10.36%4.06%P/E RatioN/A10.7749.0317.51Price / Sales7.32283.873,155.57134.92Price / CashN/A56.6530.5737.95Price / Book-5.525.382.764.94Net Income-$7.81M$151.62M$1.02B$225.30M7 Day Performance10.12%-4.82%-1.36%-1.11%1 Month Performance58.80%2.04%-0.05%7.29%1 Year PerformanceN/A16.11%16.29%23.06% Janone Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTSJanoneN/A$3.55-5.3%N/AN/A$49.95M$7.11M0.00170Positive NewsBMEABiomea Fusion3.8639 of 5 stars$5.85+3.7%$39.36+572.9%-67.3%$212.00MN/A-1.4150Analyst ForecastShort Interest ↑News CoverageSOPHSOPHiA GENETICS2.8722 of 5 stars$3.23-1.5%$6.50+101.2%-24.2%$211.18M$62.37M-3.01520Analyst ForecastGap UpXBITXBiotech0.5042 of 5 stars$6.92-0.4%N/A+44.9%$210.94M$4.01M-6.41100INBXInhibrx1.5779 of 5 stars$14.56-0.4%N/A-48.3%$210.77M$1.57M0.00166Short Interest ↑News CoverageLFVNLifeVantage3.1965 of 5 stars$16.49+2.8%N/A+165.2%$206.54M$196.01M50.13260Positive NewsHigh Trading VolumeCRDFCardiff Oncology2.1616 of 5 stars$4.03+2.8%$10.33+156.4%+282.1%$206.05M$490,000.00-4.1720Short Interest ↑CMPXCompass Therapeutics2.9417 of 5 stars$1.49+2.1%$6.75+353.0%-3.8%$205.01M$850,000.00-4.0720MGNXMacroGenics3.8093 of 5 stars$3.23+0.9%$7.63+136.1%-63.9%$202.72M$139.77M-2.03430Positive NewsPRQRProQR Therapeutics2.4096 of 5 stars$2.47-12.7%$7.60+207.7%+36.7%$201.75M$7.05M-8.13180Gap DownHigh Trading VolumeSLNSilence Therapeutics3.6694 of 5 stars$6.74+4.5%$57.20+748.7%-59.4%$201.73M$31.55M-4.11100 Related Companies and Tools Related Companies BMEA Alternatives SOPH Alternatives XBIT Alternatives INBX Alternatives LFVN Alternatives CRDF Alternatives CMPX Alternatives MGNX Alternatives PRQR Alternatives SLN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALTS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectCrypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janone Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janone With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALTS Stock Alerts